rac-(1H-imidazol-2-yl)-[1-(toluene-4-sulfonyl)-1,2,3,4-tetrahydro-quinolin-4-yl]-methanone | 945390-23-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: rac-(1H-imidazol-2-yl)-[1-(toluene-4-sulfonyl)-1,2,3,4-tetrahydro-quinolin-4-yl]-methanone
• 英文别名: 1H-imidazol-2-yl-[1-(4-methylphenyl)sulfonyl-3,4-dihydro-2H-quinolin-4-yl]methanone
• CAS: 945390-23-8
• 化学式: C₂₀H₁₉N₃O₃S
• 分子量: 381.455
• InChiKey: YGDKNJJKBYIIHR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  27
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  91.5
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  rac-(1H-imidazol-2-yl)-[1-(toluene-4-sulfonyl)-1,2,3,4-tetrahydro-quinolin-4-yl]-methanone 在 sodium hydroxide 、 肼 作用下， 以 三乙二醇 为溶剂， 反应 3.0h， 以19%的产率得到rac-4-(1H-imidazol-2-ylmethyl)-1-(toluene-4-sulfonyl)-1,2,3,4-tetrahydro-quinoline
  参考文献：
  名称：

  WO2007/85558

  摘要：

  公开号：
• 作为产物：
  描述：

  rac-1-(toluene-4-sulfonyl)-1,2,3,4-tetrahydro-quinoline-4-carboxylic acid methoxy-methyl-amide 、 1-(diethoxymethyl)-1H-imidazole 在 正丁基锂 、 盐酸 、 水 、 碳酸氢钠 作用下， 以 四氢呋喃 、 正己烷 为溶剂， 反应 1.0h， 以52%的产率得到rac-(1H-imidazol-2-yl)-[1-(toluene-4-sulfonyl)-1,2,3,4-tetrahydro-quinolin-4-yl]-methanone
  参考文献：
  名称：

  WO2007/85558

  摘要：

  公开号：

文献信息

• Methods for treating CNS disorders with bicyclo-substituted 2-imidazoline and 2-imidazoles
  申请人：Galley Guido

  公开号：US20070197620A1

  公开（公告）日：2007-08-23

  The present invention relates to a method for treating a disorder selected from depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder, stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders which comprises administering to an individual a therapeutically effective amount of a compound of formula I wherein R 1 , R 2 , Q, W, X, Y, m, and n are as defined in the specification d or not; and their pharmaceutically active salts, racemic mixtures, enantiomers, optical isomers and tautomeric forms. The invention also relates to novel compounds of formula I, compositions containing them, and methods for their preparation.

  本发明涉及一种治疗选自抑郁症、焦虑症、双相情感障碍、注意力缺陷多动症、压力相关疾病、精神疾病如精神分裂症、神经疾病如帕金森病、神经退行性疾病如阿尔茨海默病、癫痫、偏头痛、高血压、物质滥用和代谢性疾病如进食障碍、糖尿病、糖尿病并发症、肥胖症、脂质代谢异常、能量消耗和同化障碍、体温稳态障碍和功能障碍、睡眠和昼夜节律障碍以及心血管疾病的方法，包括向个体施用化合物I的治疗有效量，其中化合物I的公式为R1，R2，Q，W，X，Y，m和n如规范中所定义的，或不定义；以及它们的药物活性盐，外消旋混合物，对映异构体，光学异构体和互变异构体形式。本发明还涉及公式I的新化合物，包含它们的组合物以及其制备方法。
• METHODS FOR TREATING CNS DISORDERS WITH BICYCLO-SUBSTITUTED 2-IMIDAZOLINE AND 2-IMIDAZOLES
  申请人：Galley Guido

  公开号：US20120071506A1

  公开（公告）日：2012-03-22

  The present invention relates to a method for treating a disorder selected from depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder, stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders which comprises administering to an individual a therapeutically effective amount of a compound of formula I wherein R 1 , R 2 , Q, W, X, Y, m, and n are as defined in the specification, and their pharmaceutically active salts, racemic mixtures, enantiomers, optical isomers and tautomeric forms. The invention also relates to novel compounds of formula I, compositions containing them, and methods for their preparation.

  本发明涉及一种治疗选自抑郁症、焦虑症、双相情感障碍、注意力缺陷多动障碍、与压力有关的障碍、精神病性障碍如精神分裂症、神经疾病如帕金森病、神经退行性疾病如阿尔茨海默病、癫痫、偏头痛、高血压、物质滥用和代谢障碍如进食障碍、糖尿病、糖尿病并发症、肥胖症、脂质代谢异常、能量消耗和吸收障碍、体温稳态障碍和功能障碍、睡眠和昼夜节律障碍以及心血管障碍的方法，包括向个体施用公式I化合物的治疗有效量，其中R1、R2、Q、W、X、Y、m和n在说明书中定义，以及它们的药物活性盐、混合物、对映体、光学异构体和互变异构体。本发明还涉及公式I的新化合物、含有它们的组合物以及其制备方法。
• [EN] USE OF 2-IMIDAZOLES FOR THE TREATMENT OF CNS DISORDERS<br/>[FR] UTILISATION DE 2-IMIDAZOLES POUR LE TRAITEMENT DE TROUBLES DU SNC
  申请人：HOFFMANN LA ROCHE

  公开号：WO2007085558A1

  公开（公告）日：2007-08-02

  [EN] The present invention relates to the use of compounds of formula (I) R¹ is hydrogen, tritium, hydroxy, lower alkyl, lower alkoxy, halogen, nitro, amino or lower alkyl substituted by halogen; R² is hydrogen, hydroxy or lower alkyl; X is N and Y is CH or CH2 or CH-lower alkyl or X is CH and Y is N; Q is CH₂, O, NH, N-alkyl or N-SO₂-alkyl or N-SO₂-toluen-4-yl; W is CH₂ or a bond are independently from one another 1, 2 or 3; when m is 2 or 3, R² may m, n be the same or not; when n is 2 or 3, R¹ may be the same or not; the dotted lines may each be independently from one another a bond or not; and to their pharmaceutically active salts, racemic mixtures, enantiomers, optical isomers and tautomeric forms of compounds of formula (I) for the preparation of medicaments for the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder, stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.
  [FR] La présente invention concerne l'utilisation de composés de formule (I), dans laquelle R¹ est hydrogène, tritium, hydroxy, alkyle inférieur, alcoxy inférieur, halogène, nitro, amino ou alkyle inférieur substitué par halogène; R² est hydrogène hydroxy ou alkyle inférieur; X est N et Y est CH ou CH2 ou CH-alkyle inférieur, ou bien X est CH et Y est N; Q est CH₂, O, NH, N-alkyle ou N-SO₂-alkyle ou N-SO₂-toluène-4-yle; W est CH₂ ou une liaison, et sont, indépendamment l'un de l'autre, 1, 2 ou 3; quand m est 2 ou 3, R² peut être m, n peut être identique ou non; quand n est 2 ou 3, R¹ peut être identique ou non, les lignes discontinues peuvent être chacune, indépendamment l'unw de l'autre, une liaison ou non. L'invention concerne les sels pharmaceutiquement actifs, mélanges racémiques, énantiomères, isomères actifs et formes tautomères des composés de formule (I) destinés à la préparation de médicaments servant au traitement de la dépression, des troubles anxieux, du trouble bipolaire, du trouble d'hyperactivité avec déficit de l'attention, des troubles liés au stress, des troubles psychotiques tels que la schizophrénie, des maladies neurologiques telles que la maladie de Parkinson, des troubles neurodégénératifs tels que la maladie d'Alzheimer, de l'épilepsie, de la migraine, de l'hypertension, de l'abus de substances psychoactives, et de troubles métaboliques tels que les troubles de la nutrition, le diabète, les complications diabétiques, l'obésité, la dyslipidémie, les troubles de la consommation et de l'assimilation d'énergie, les troubles et dysfonctionnements de l'homéostasie de la température corporelle, les troubles du sommeil et du rythme circadien, et les troubles cardiovasculaires.
• WO2007/85558
  申请人：——

  公开号：——

  公开（公告）日：——